0.12%| Prev Close: | 0.33 |
|---|---|
| Open: | 0.32 |
| Bid: | 0.25 x 200 |
| Ask: | 0.34 x 200 |
| 1y Target Est: | 1.50 |
| Beta: | 1.45 |
| Next Earnings Date: | N/A |
| Day's Range: | 0.31 - 0.33 |
|---|---|
| 52wk Range: | 0.28 - 0.81 |
| Volume: | 111,705 |
| Avg Vol (3m): | 351,706 |
| Market Cap: | 37.03M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.05 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap ConferencePR Newswire(Mon, May 20)
- REXAHN PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A first-in-class inhibitor of p68 helicase for the treatment of solid tumors at AACR Annual Meeting 2013Business Wire(Tue, Apr 2)
- REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles ofEDGAR Online(Fri, Mar 29)
- REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual ReportEDGAR Online(Fri, Mar 22)
- Rexahn Pharmaceuticals to Present at the 25th Annual ROTH ConferenceBusiness Wire(Mon, Mar 11)
- Rexahn says to continue RX-3117 development with Tevaat theflyonthewall.com(Tue, Feb 19)
- Rexahn Pharmaceuticals Provides Key Goals for 2013Business Wire(Tue, Feb 19)
- U.S. Food and Drug Administration Approved 30% More Drugs in 2012Marketwired(Tue, Feb 12)
- Cancer Stocks To Watchat Seeking Alpha(Mon, Feb 11)
- Rexahn initiated with a Buy at Maximat theflyonthewall.com(Wed, Jan 30)
- REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements andEDGAR Online(Tue, Jan 22)
- 4 Healthcare Stock Stories for Investor Well-Beingat Wall St. Cheat Sheet(Tue, Jan 22)
- Rexahn Pharmaceuticals Appoints Peter D. Suzdak as Chief Executive OfficerBusiness Wire(Tue, Jan 22)
Press Releases
- Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap ConferencePR Newswire(Mon, May 20)
- Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A first-in-class inhibitor of p68 helicase for the treatment of solid tumors at AACR Annual Meeting 2013Business Wire(Tue, Apr 2)
- Rexahn Pharmaceuticals to Present at the 25th Annual ROTH ConferenceBusiness Wire(Mon, Mar 11)
Reports
- Thomson Reuters Stock Report - REXAHN PHARMACEUTICALS INC. (RNN-A)Thomson Reuters Stock Report(May 20)
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(May 20)
- REXAHN PHARMACEUTICALS INC (RNN) 12-months forecastPechala's Reports(May 18)